Patents by Inventor George Robert Mabry, III

George Robert Mabry, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11905329
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: February 20, 2024
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Anti-PD-1 Antibodies and Uses Thereof
    Publication number: 20230018445
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: January 19, 2023
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11384147
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: July 12, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Anti-PD-1 Antibodies and Uses Thereof
    Publication number: 20200399374
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: April 10, 2020
    Publication date: December 24, 2020
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Antibodies to PD-1 and uses thereof
    Patent number: 10654929
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 19, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • ANTIBODIES TO PD-1 AND USES THEREOF
    Publication number: 20180118829
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: November 1, 2017
    Publication date: May 3, 2018
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Methods of inhibiting inflammation with antagonists to IL-17A, IL-17F, and IL-23P19
    Patent number: 8333968
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: December 18, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
  • ANTAGONISTS OF IL-17A, IL-17F, AND IL-23P19
    Publication number: 20120294862
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: June 27, 2012
    Publication date: November 22, 2012
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
  • METHODS OF INHIBITING INFLAMMATION WITH ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19
    Publication number: 20110159589
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: February 22, 2011
    Publication date: June 30, 2011
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
  • Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
    Patent number: 7910703
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: April 28, 2008
    Date of Patent: March 22, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
  • ANTAGONISTS TO IL-17A, IL-17F, AND IL-23P19 AND METHODS OF USE
    Publication number: 20080299129
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Application
    Filed: April 28, 2008
    Publication date: December 4, 2008
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber